Stock, pipeline and biotech catalyst intelligence
Reported statements
| USD | 2025 |
|---|---|
| Revenue | — |
| R&D expense | $100.6M |
| Operating income | −$122.1M |
| Net income | −$105.4M |
| Cash & equivalents | $46.9M |
| Total debt | $1.9M |
| Operating cash flow | −$88.2M |
| Free cash flow | −$88.4M |
Company profile
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.